Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Alzheimers Dement. 2020 Sep 11;16(10):1345–1357. doi: 10.1002/alz.12144

Figure 4.

Figure 4.

1.5-month old 5XFAD mice treated with 51657 for 7 weeks have reduced cortical and hippocampal/subiculum soluble Aβ. A. Soluble Aβ42 in the combined cortex and hippocampus/subiculum of 5XFAD study mice after normalization to the vehicle mean for each sex, with n=4 vehicle- and 51657-treated male and female 5XFAD mice. Statistical comparison was by unpaired 2-tailed t-test (t=2.28, df=14). Error bars represent SEM. B. Soluble Aβ42 in the cortex (Ctx) and hippocampus/subiculum (Hip) of the 5XFAD study mice graphed by sex, with normalization to the vehicle mean from the female hippocampus/subiculum group. Error bars represent SEM. C. Correlation plot of the relative soluble and insoluble Aβ42 in combined cortical and hippocampal/subiculum samples from the 5XFAD study mice. Data underwent linear fit analysis, with r2 and p-value shown in the graph and dashed lines representing the 95% confidence interval. Circles=Vehicle; Squares=51657-treated.